Tricagrelor a platelet aggregation inhibitor used in ST elevation coronary syndrome is being compared to clopidogrel in its use in ACS without ST elevation. Here is the study proving it to be even better than clopidogrel.

Team@CMHF

AstraZeneca today announced BRILIQUE (ticagrelor), a new oral antiplatelet medicine, received a Class I recommendation (level of evidence B) from the European Society of Cardiology (ESC) in the revised “Guidelines for Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation.”

In these 2011 guidelines, ticagrelor is recommended for all non-ST elevation ACS patients at moderate-to-high risk of ischaemic events, regardless of initial treatment strategy and including those pre-treated with clopidogrel (which should be discontinued when ticagrelor is commenced) (Class 1, level of evidence B). In addition, the guidelines recommend ticagrelor be considered for initiation or resumption following coronary artery bypass graft (CABG) surgery as soon as it is considered safe (Class IIa, level of evidence B).

ABOUT PLATO
PLATO was a large (18,624 patients in 43 countries), head-to-head patient outcomes study of ticagrelor versus clopidogrel, both given in combination with aspirin and other standard therapy, designed to establish whether ticagrelor could achieve a clinically meaningful reduction in CV end points in ACS patients, above and beyond those afforded by clopidogrel.

The results of this analysis formed the basis of the recommendation in all of the approved BRILIQUE labels that patients taking BRILIQUE should also take a low-maintenance dose of aspirin daily, unless specifically contraindicated

About BRILIQUE (ticagrelor tablets)
BRILIQUE is an oral antiplatelet treatment for ACS. BRILIQUE is a direct-acting P2Y12 receptor antagonist in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILIQUE is the first reversibly-binding oral ADP receptor antagonist to be approved for use in ACS.

BRILINTA has now been approved in 43 countries, including in the European Union under the trade name BRILIQUE and in the United States, Canada, Brazil, Malaysia and Macau under the trade name BRILINTA. BRILINTA is currently under regulatory review in 49 countries, including Russia, India and China.

Ref: http://www.newswire.ca/en/releases/archive/August2011/30/c7091.html